Share

September 2017; 4 (5) Clinical/Scientific NotesOpen Access

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal

Giovanni Novi, Angelo Ghezzi, Matteo Pizzorno, Caterina Lapucci, Fabio Bandini, Pietro Annovazzi, Giovanni L. Mancardi, Antonio Uccelli
First published July 27, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000377
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
977

Share

This article has a correction. Please see:

Article Information

vol. 4 no. 5 e377
DOI: 
https://doi.org/10.1212/NXI.0000000000000377
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received January 12, 2017
  • Accepted in final form May 11, 2017
  • First Published July 27, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Giovanni Novi, MD,
    2. Angelo Ghezzi, MD,
    3. Matteo Pizzorno, MD,
    4. Caterina Lapucci, MD,
    5. Fabio Bandini, MD,
    6. Pietro Annovazzi, MD,
    7. Giovanni L. Mancardi, MD, PhD and
    8. Antonio Uccelli, MD, PhD
  1. Giovanni Novi, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Angelo Ghezzi, MD,
    3. Scientific Advisory Boards:

    1. Novartis, advisory board of a trial in pediatric MS

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Multiple Sclerosis International, no compensation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Merck Serono, speaker in a scientific meeting Biogen Idec, speaker in a scientific meeting Novartis, speaker in a scientific meeting Genzyme, speaker in a scientific meeting Teva, speaker in a scientific meeting

    Consultancies:

    1. Novartis, consulting activity Biogen, consulting activity Mylan, consulting activity Roche, consulting activity

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Matteo Pizzorno, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Caterina Lapucci, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Fabio Bandini, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Pietro Annovazzi, MD,
    7. Scientific Advisory Boards:

    1. Dr. Annovazzi served on advisory boards for Novartis, Genzyme, Teva, Roche, Merck-Serono and Biogen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Annovazzi received speaking honoraria from Teva Italia, Novartis, Genzyme, Merck-Serono and Biogen

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Giovanni L. Mancardi, MD, PhD and
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Honoraria for lecturing , travel expenses for attending meetings and finacial support for research from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi- Aventis and Teva Pharmaceuticals

    Editorial Boards:

    1. Associate Editor of Neurological Sciences

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Honoraria for speaking activities from Companies (Biogen Idec, Bayer Schering)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Italian Multiple Sclerosis Society (AISM) Grants 2001-R- 38 and 2002-R-36

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Antonio Uccelli, MD, PhD
    9. Scientific Advisory Boards:

    1. Served on the Scientific Advisory Boards for Genetech (2009), Roche 2009- present), Allergan 2009-present

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Received funding for a trip to give a lecture from Athersys (2009)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Received honoraria to give lectures from Biogen Dompe', Serono Symposia, Sanofi Aventis, Tohoku University Graduate School of Medicine.

    Consultancies:

    1. Received consulting fee from Merck-Serono (2009), Biogen Domp? (2010)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received grant support from Bayer Schering (2009) and Sanofi Aventis (2009)

    Research Support, Government Entities:

    1. Funded as Principal Investigator from Italian Ministry of Health (RF-LIG- 2007-647513) (2008-2010), from the Regione Liguria, Progetto LIMONTE (2009-2010), Ricerca Sanitaria Regionale (2010)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Funded as Principal Investigator from the Fondazione Italiana Sclerosi Multipla (Progetto Speciale Cellule Staminali (2008-present), Fondazione CARIGE (2008-present)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) (N.G., C.L., G.L.M., A.U.), University of Genoa, Italy; Multiple Sclerosis Study Center (A.G., P.A.), Hospital of Gallarate, Italy; San Paolo Hospital (M.P., F.B.), Savona, Italy; and IRCCS AUO San Martino—IST (G.L.M., A.U.), Genoa, Italy.
  1. Correspondence to Dr. Novi: giovanninovi{at}gmail.com
View Full Text

Article usage

Article usage: July 2017 to September 2021

AbstractFullPdfSource
Jul 20176738420Highwire
Aug 201724210451Highwire
Aug 2017416983pmc
Sep 201723433765Highwire
Sep 2017225366pmc
Oct 201774116455Highwire
Oct 2017286070pmc
Nov 2017392221Highwire
Nov 2017214246pmc
Dec 20172198Highwire
Jan 201802410Highwire
Feb 20180417Highwire
Mar 201822810Highwire
Apr 20182377Highwire
Apr 2018143238pmc
May 201826011Highwire
Jun 20181529Highwire
Jun 201861517pmc
Jul 20188476Highwire
Aug 20182367Highwire
Aug 201832429pmc
Sep 20181303Highwire
Oct 20181628Highwire
Nov 20183375Highwire
Dec 20181797Highwire
Jan 20191576Highwire
Feb 20197484Highwire
Mar 20191208Highwire
Apr 201924911Highwire
May 20193226Highwire
Jun 20193194Highwire
Jul 20193326Highwire
Aug 20195196Highwire
Sep 20191114Highwire
Oct 20191744Highwire
Nov 201923510Highwire
Dec 20193667Highwire
Jan 20203123Highwire
Feb 202021515Highwire
Mar 202022010Highwire
Apr 2020372Highwire
May 20207818Highwire
Jun 20206235Highwire
Jul 202012015Highwire
Aug 20200395Highwire
Sep 202075331Highwire
Oct 20204346Highwire
Nov 202042519Highwire
Dec 20205157Highwire
Jan 20217299Highwire
Feb 202187217Highwire
Mar 202122015Highwire
Apr 20214169Highwire
May 20215194Highwire
Jun 202152415Highwire
Jul 202162716Highwire
Aug 20212262Highwire
Sep 202112819Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

Topics Discussed

Alert Me

Advertisement